Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair
NCT ID: NCT02915042
Last Updated: 2019-02-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE4
Study Classification
INTERVENTIONAL
Study Start Date
2017-12-31
Study Completion Date
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study is to evaluate the efficacy of administering intravenous dexmedetomidine as a single preemptive dose to placebo in reducing the total 24 hour dose of opioids as measured on a weight adjusted morphine equivalent basis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
NCT02633241
Epilepsy
Cerebral Palsy
Developmental Delay
COMPLETED
PHASE4
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
NCT02810899
Brain Neoplasms
COMPLETED
PHASE4
Length of Hospital Stay and Postoperative Analgesic Requirements After Introduction of a Specific Maxillary Nerve Block in Children Undergoing Cleft Palate Surgery
NCT07279883
Cleft Palate Children
RECRUITING
Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy
NCT02244515
Emergence Deliruim; Cerebral Palsy
UNKNOWN
PHASE4
The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery
NCT01512355
Strabismus
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The eligibility of the patient to participate in this study will be determined by the Investigator on the basis of the inclusion and exclusion criteria. Consent will be obtained from eligible patients only.
The following is the standard intraoperative anesthesia protocol utilized at Texas Children's Hospital for all children undergoing this procedure of cleft palate repair even if they are not part of the study: (1) Induction of anesthesia via a face mask with sevoflurane 6-8% and 70% N2O / 30% O2 (2) A peripheral IV will be inserted and glycopyrrolate 5-10 mcg/kg IV administered to dry oral secretions and reduce vagal responses. (3) Tracheal intubation using appropriate equipment in keeping with the clinical judgment of the anesthesia care provider. The protocol will permit the administration of propofol up to 3 mg/kg over 20-30 seconds to increase the depth of anesthesia prior to tracheal intubation if the Attending Anesthesiologist deems it necessary. (4) General anesthesia maintained with Sevoflurane/isoflurane with inhaled concentrations adjusted to keep blood pressure and heart rates within 20% of baseline. (5) Nitrous oxide will be discontinued and the lowest inspired oxygen concentration will be administered to reduce risks of airway fires while avoiding hypoxemia. (6) Fentanyl 1-2 mcg/kg administered at the start of the procedure with subsequent fentanyl 1 mcg/kg boluses as needed if the heart rate and blood pressure are increased per vital signs (HR and BP) variance greater than 20% of baseline (7) Dexamethasone 0.5 mg/kg IV. (8) Rocuronium 0.6 -1 mg/kg IV may be administered for paralysis if this is clinically indicated in the opinion of the Attending Anesthesiologist. (9) Local infiltration with 0.5% lidocaine with 1:200,000 epinephrine will be administered by the surgeon at the site of the palatoplasty in keeping with our current surgeon practice. (10) Ondansetron 0.1 mg/kg IV at the end of the procedure (11) Anesthetic gases will be discontinued at the end of the procedure and 100% oxygen administered prior to tracheal extubation. If rocuronium was used neuromuscular blockade will be antagonized with neostigmine 0.07 mg/kg and glycopyrrolate 10 mcg/kg. The timing of tracheal extubation will be based on clinical indications and the judgment of the Attending Anesthesiologist.
The above standardized management will be followed for all children undergoing this operation even if they are not part of the study. The experimental part of the protocol will involve randomization of subjects in a 1:1 ratio to receive intravenous dexmedetomidine or placebo. Randomization will occur by the pharmacy using a computer generated random number. The study will be double-blind with respect to the treatment assignment. The investigational pharmacy will mix and deliver either dexmedetomidine 1 mcg/kg in a concentration of 4 mcg/ml or placebo to the anesthesia provider on the day of surgery. The assigned study drug will be administered when the heart rate and blood pressure have returned to acceptable stable levels after tracheal intubation and before the surgeon has started the palatal injection of lidocaine with epinephrine. Placebo or dexmedetomidine will be administered in a similar fashion as an IV infusion over 10 minutes as recommended to avoid bradycardia,hypertension, hypotension or other cardiac events. . Persistent bradycardia (greater than 30% reduction from baseline for more than 1 minute) will be managed with administration of atropine 0.01 mg/kg. An immediate rise in blood pressure will be treated with an increase in the inspired concentration of inhaled anesthetics. If there is hypertension (greater than 30% rise in value from baseline), the inspired concentration of inhaled anesthetics will be increased. Persistent hypotension (greater than 30% decrease from baseline levels for more than 1 minute) will be treated with fluid bolus of 5-10 ml/kg and decreasing the concentration of the volatile anesthetic. Other drugs may be used in keeping with the clinical judgment of the Attending Anesthesiologist.
Postoperative management will not be changed for the purposes of the study. In keeping with standard practices in the TCH, all patients in the PACU will be monitored with continuous pulse oximetry, EKG and serial non-invasive blood pressure measurements. Pain will be assessed using an age appropriate observational scale- the FLACC score for younger patients and the FACES score for older co-operative patients. Pain scores are recorded on arrival to the PACU, when awake and at 30 minute intervals. If the FLACC score is greater than 4 or the FACES greater than 2, patients will receive morphine 25 mcg/kg IV to be repeated as required in 10 minutes if adequate pain control has not been achieved. Supplemental oxygen will be administered till the child can maintain an oxygen saturation greater than 92% in room air. Emergence delirium will be determined using the PAED score and children with scores of greater than 12 will receive therapy in keeping with the clinical judgment of the Attending Anesthesiologist (additional opioids or IV propofol). The child will be discharged to the floor when awake, can maintain patency of the airway, have stable vital signs, a pain score less than 4 and an Aldrete score of at least 9.
Patients will be transferred to the floor where they will receive the current standard postoperative regimen used by our plastic surgery service care for this procedure. This will includeHycet 0.135mg/kg every 4 hours when needed. Morphine 0.025 mg/kg IV every 4 hours will be made available as a rescue analgesia for break through pain. Nurses record pain scores on the FLACC or FACES scale depending on the age of the patient and ability to cooperate. Rescue analgesia will be provided based on a nursing assessment that the pain is poorly controlled (FLACC score greater than 4 or FACES score greater than 2) after receiving oral pain medications. Non -steroidal anti-inflammatory drugs are usually avoided in these children because of concerns for bleeding from the raw mucosal surfaces at the site of the surgery.
We will record all perioperative, intraoperative and postoperative drugs administered to patients, pain scores, Pediatric Anesthesia Emergence Delirium (PAED) scores in the PACU, pain scores and rescue medications administered during the stay in the PACU and on the floor. The time to first rescue medication, oral intake, and discharge from the PACU and the hospital will also be recorded along with adverse events such as vomiting, constipation, pruritis, agitation, respiratory depression or excessive sedation. Any interventions to treat these will be noted.
The following is the standard intraoperative anesthesia protocol utilized at Texas Children's Hospital for all children undergoing this procedure of cleft palate repair even if they are not part of the study: (1) Induction of anesthesia via a face mask with sevoflurane 6-8% and 70% N2O / 30% O2 (2) A peripheral IV will be inserted and glycopyrrolate 5-10 mcg/kg IV administered to dry oral secretions and reduce vagal responses. (3) Tracheal intubation using appropriate equipment in keeping with the clinical judgment of the anesthesia care provider. The protocol will permit the administration of propofol up to 3 mg/kg over 20-30 seconds to increase the depth of anesthesia prior to tracheal intubation if the Attending Anesthesiologist deems it necessary. (4) General anesthesia maintained with Sevoflurane/isoflurane with inhaled concentrations adjusted to keep blood pressure and heart rates within 20% of baseline. (5) Nitrous oxide will be discontinued and the lowest inspired oxygen concentration will be administered to reduce risks of airway fires while avoiding hypoxemia. (6) Fentanyl 1-2 mcg/kg administered at the start of the procedure with subsequent fentanyl 1 mcg/kg boluses as needed if the heart rate and blood pressure are increased per vital signs (HR and BP) variance greater than 20% of baseline (7) Dexamethasone 0.5 mg/kg IV. (8) Rocuronium 0.6 -1 mg/kg IV may be administered for paralysis if this is clinically indicated in the opinion of the Attending Anesthesiologist. (9) Local infiltration with 0.5% lidocaine with 1:200,000 epinephrine will be administered by the surgeon at the site of the palatoplasty in keeping with our current surgeon practice. (10) Ondansetron 0.1 mg/kg IV at the end of the procedure (11) Anesthetic gases will be discontinued at the end of the procedure and 100% oxygen administered prior to tracheal extubation. If rocuronium was used neuromuscular blockade will be antagonized with neostigmine 0.07 mg/kg and glycopyrrolate 10 mcg/kg. The timing of tracheal extubation will be based on clinical indications and the judgment of the Attending Anesthesiologist.
The above standardized management will be followed for all children undergoing this operation even if they are not part of the study. The experimental part of the protocol will involve randomization of subjects in a 1:1 ratio to receive intravenous dexmedetomidine or placebo. Randomization will occur by the pharmacy using a computer generated random number. The study will be double-blind with respect to the treatment assignment. The investigational pharmacy will mix and deliver either dexmedetomidine 1 mcg/kg in a concentration of 4 mcg/ml or placebo to the anesthesia provider on the day of surgery. The assigned study drug will be administered when the heart rate and blood pressure have returned to acceptable stable levels after tracheal intubation and before the surgeon has started the palatal injection of lidocaine with epinephrine. Placebo or dexmedetomidine will be administered in a similar fashion as an IV infusion over 10 minutes as recommended to avoid bradycardia,hypertension, hypotension or other cardiac events. . Persistent bradycardia (greater than 30% reduction from baseline for more than 1 minute) will be managed with administration of atropine 0.01 mg/kg. An immediate rise in blood pressure will be treated with an increase in the inspired concentration of inhaled anesthetics. If there is hypertension (greater than 30% rise in value from baseline), the inspired concentration of inhaled anesthetics will be increased. Persistent hypotension (greater than 30% decrease from baseline levels for more than 1 minute) will be treated with fluid bolus of 5-10 ml/kg and decreasing the concentration of the volatile anesthetic. Other drugs may be used in keeping with the clinical judgment of the Attending Anesthesiologist.
Postoperative management will not be changed for the purposes of the study. In keeping with standard practices in the TCH, all patients in the PACU will be monitored with continuous pulse oximetry, EKG and serial non-invasive blood pressure measurements. Pain will be assessed using an age appropriate observational scale- the FLACC score for younger patients and the FACES score for older co-operative patients. Pain scores are recorded on arrival to the PACU, when awake and at 30 minute intervals. If the FLACC score is greater than 4 or the FACES greater than 2, patients will receive morphine 25 mcg/kg IV to be repeated as required in 10 minutes if adequate pain control has not been achieved. Supplemental oxygen will be administered till the child can maintain an oxygen saturation greater than 92% in room air. Emergence delirium will be determined using the PAED score and children with scores of greater than 12 will receive therapy in keeping with the clinical judgment of the Attending Anesthesiologist (additional opioids or IV propofol). The child will be discharged to the floor when awake, can maintain patency of the airway, have stable vital signs, a pain score less than 4 and an Aldrete score of at least 9.
Patients will be transferred to the floor where they will receive the current standard postoperative regimen used by our plastic surgery service care for this procedure. This will includeHycet 0.135mg/kg every 4 hours when needed. Morphine 0.025 mg/kg IV every 4 hours will be made available as a rescue analgesia for break through pain. Nurses record pain scores on the FLACC or FACES scale depending on the age of the patient and ability to cooperate. Rescue analgesia will be provided based on a nursing assessment that the pain is poorly controlled (FLACC score greater than 4 or FACES score greater than 2) after receiving oral pain medications. Non -steroidal anti-inflammatory drugs are usually avoided in these children because of concerns for bleeding from the raw mucosal surfaces at the site of the surgery.
We will record all perioperative, intraoperative and postoperative drugs administered to patients, pain scores, Pediatric Anesthesia Emergence Delirium (PAED) scores in the PACU, pain scores and rescue medications administered during the stay in the PACU and on the floor. The time to first rescue medication, oral intake, and discharge from the PACU and the hospital will also be recorded along with adverse events such as vomiting, constipation, pruritis, agitation, respiratory depression or excessive sedation. Any interventions to treat these will be noted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cleft Palate
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
Group Type
EXPERIMENTAL
Dexmedetomidine
Intervention Type
DRUG
Analgesic Efficacy
Placebo group
Intervention group 2: placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Saline placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Analgesic Efficacy
Intervention Type
DRUG
Placebo
Saline placebo
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Precedex
Saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients between 6mo to 8 years of age scheduled to undergo primary or secondary cleft repair.
Exclusion Criteria
* Patients with significant cognitive impairment
* Patients with various syndromes known to be associated with difficult airways(e.g. Goldenhar's syndrome, Treacher- Collins, Trisomy 13 or 18, Pierre Robin, etc.)
* Have a prior history of allergy, hypersensitivity or contraindication to any drug used for anesthesia including opioids (morphine, fentanyl, hydrocodone) and inhalation agents(i.e. children with susceptibility to malignant hyperthermia)
* Have a history of congenital bleeding diathesis(e.g. hemophilia) or any active clinically significant bleeding, impaired renal or hepatic function
* Children with heart failure, heart block, ventricular dysfunction, cardiomyopathy, myocarditis or congenital heart disease where cardiac output is rate dependent and relies on A-V synchrony (e.g. single ventricle). Children with well controlled atrial or ventricular septal defects, patent ductus arteriosus, repaired coarctation of the aorta will qualify if they have no cardiac rhythm or hypertension problems.
* Children with uncontrolled hypertension, intracranial vascular malformations, Moya Moya disease or intracranial hypertension.
* Any child who has received an investigational drugs within 30 days before study drug administration.
* Inability of the parent or legal guardian to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board) and agree to abide by the study restrictions.
* Be otherwise unsuitable for the study, in the opinion of the Investigator.
* Patients with various syndromes known to be associated with difficult airways(e.g. Goldenhar's syndrome, Treacher- Collins, Trisomy 13 or 18, Pierre Robin, etc.)
* Have a prior history of allergy, hypersensitivity or contraindication to any drug used for anesthesia including opioids (morphine, fentanyl, hydrocodone) and inhalation agents(i.e. children with susceptibility to malignant hyperthermia)
* Have a history of congenital bleeding diathesis(e.g. hemophilia) or any active clinically significant bleeding, impaired renal or hepatic function
* Children with heart failure, heart block, ventricular dysfunction, cardiomyopathy, myocarditis or congenital heart disease where cardiac output is rate dependent and relies on A-V synchrony (e.g. single ventricle). Children with well controlled atrial or ventricular septal defects, patent ductus arteriosus, repaired coarctation of the aorta will qualify if they have no cardiac rhythm or hypertension problems.
* Children with uncontrolled hypertension, intracranial vascular malformations, Moya Moya disease or intracranial hypertension.
* Any child who has received an investigational drugs within 30 days before study drug administration.
* Inability of the parent or legal guardian to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board) and agree to abide by the study restrictions.
* Be otherwise unsuitable for the study, in the opinion of the Investigator.
Minimum Eligible Age
6 Months
Maximum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor College of Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chris Glover
Dr. Chris Darrel Glover Assistant Professor Anesthesiology Texas Children's Hospital Baylor College of Medicine
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chris D. Glover, MD
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine - Texas Children's Hospital
References
Explore related publications, articles, or registry entries linked to this study.
Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012 May;129(5):e1343-7. doi: 10.1542/peds.2011-2538. Epub 2012 Apr 9.
Reference Type
BACKGROUND
Mason KP, Lerman J. Review article: Dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011 Nov;113(5):1129-42. doi: 10.1213/ANE.0b013e31822b8629. Epub 2011 Aug 4.
Reference Type
BACKGROUND
Pickard A, Davies P, Birnie K, Beringer R. Systematic review and meta-analysis of the effect of intraoperative alpha(2)-adrenergic agonists on postoperative behaviour in children. Br J Anaesth. 2014 Jun;112(6):982-90. doi: 10.1093/bja/aeu093. Epub 2014 Apr 11.
Reference Type
BACKGROUND
Sun Y, Lu Y, Huang Y, Jiang H. Is dexmedetomidine superior to midazolam as a premedication in children? A meta-analysis of randomized controlled trials. Paediatr Anaesth. 2014 Aug;24(8):863-74. doi: 10.1111/pan.12391. Epub 2014 Mar 26.
Reference Type
BACKGROUND
Schnabel A, Reichl SU, Poepping DM, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of intraoperative dexmedetomidine for acute postoperative pain in children: a meta-analysis of randomized controlled trials. Paediatr Anaesth. 2013 Feb;23(2):170-9. doi: 10.1111/pan.12030. Epub 2012 Oct 9.
Reference Type
BACKGROUND
Olutoye OA, Glover CD, Diefenderfer JW, McGilberry M, Wyatt MM, Larrier DR, Friedman EM, Watcha MF. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010 Aug;111(2):490-5. doi: 10.1213/ANE.0b013e3181e33429. Epub 2010 Jul 7.
Reference Type
BACKGROUND
Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M, Lerman J. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology. 2006 Dec;105(6):1098-110. doi: 10.1097/00000542-200612000-00009.
Reference Type
BACKGROUND
Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. Paediatr Anaesth. 2009 Nov;19(11):1119-29. doi: 10.1111/j.1460-9592.2009.03133.x. Epub 2009 Aug 25.
Reference Type
BACKGROUND
Mason KP, Robinson F, Fontaine P, Prescilla R. Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. Radiology. 2013 Jun;267(3):911-7. doi: 10.1148/radiol.13121232. Epub 2013 Feb 28.
Reference Type
BACKGROUND
Tobias JD, Gupta P, Naguib A, Yates AR. Dexmedetomidine: applications for the pediatric patient with congenital heart disease. Pediatr Cardiol. 2011 Dec;32(8):1075-87. doi: 10.1007/s00246-011-0092-8. Epub 2011 Sep 10.
Reference Type
BACKGROUND
Chen ZF, Chen YK, Guo Y, Jiang H. [Effect of dexmedetomidine on emergence agitation after oral and maxillofacial surgery]. Shanghai Kou Qiang Yi Xue. 2013 Dec;22(6):698-701. Chinese.
Reference Type
BACKGROUND
Patel A, Davidson M, Tran MC, Quraishi H, Schoenberg C, Sant M, Lin A, Sun X. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010 Oct;111(4):1004-10. doi: 10.1213/ANE.0b013e3181ee82fa. Epub 2010 Aug 12.
Reference Type
BACKGROUND
Nour C, Ratsiu J, Singh N, Mason L, Ray A, Martin M, Hassanian M, Uhler J, Applegate RL 2nd. Analgesic effectiveness of acetaminophen for primary cleft palate repair in young children: a randomized placebo controlled trial. Paediatr Anaesth. 2014 Jun;24(6):574-81. doi: 10.1111/pan.12393. Epub 2014 Apr 2.
Reference Type
BACKGROUND
Kayyal TA, Wolfswinkel EM, Weathers WM, Capehart SJ, Monson LA, Buchanan EP, Glover CD. Treatment effects of dexmedetomidine and ketamine on postoperative analgesia after cleft palate repair. Craniomaxillofac Trauma Reconstr. 2014 Jun;7(2):131-8. doi: 10.1055/s-0034-1371446. Epub 2014 Feb 28.
Reference Type
BACKGROUND
Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med. 2002 Oct 3;347(14):1094-103. doi: 10.1056/NEJMra012626. No abstract available.
Reference Type
BACKGROUND
Lonnqvist PA, Morton NS. Postoperative analgesia in infants and children. Br J Anaesth. 2005 Jul;95(1):59-68. doi: 10.1093/bja/aei065. Epub 2005 Jan 21. No abstract available.
Reference Type
BACKGROUND
Mason KP, Zurakowski D, Zgleszewski S, Prescilla R, Fontaine PJ, Dinardo JA. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth. 2010 Jun;20(6):516-23. doi: 10.1111/j.1460-9592.2010.03299.x. Epub 2010 Apr 14.
Reference Type
BACKGROUND
Mascha EJ, Turan A. Joint hypothesis testing and gatekeeping procedures for studies with multiple endpoints. Anesth Analg. 2012 Jun;114(6):1304-17. doi: 10.1213/ANE.0b013e3182504435. Epub 2012 May 3.
Reference Type
BACKGROUND
Dai F, Silverman DG, Chelly JE, Li J, Belfer I, Qin L. Integration of pain score and morphine consumption in analgesic clinical studies. J Pain. 2013 Aug;14(8):767-77.e8. doi: 10.1016/j.jpain.2013.04.004. Epub 2013 Jun 3.
Reference Type
BACKGROUND
Farag E, Atim A, Ghosh R, Bauer M, Sreenivasalu T, Kot M, Kurz A, Dalton JE, Mascha EJ, Mounir-Soliman L, Zaky S, Ali Sakr Esa W, Udeh BL, Barsoum W, Sessler DI. Comparison of three techniques for ultrasound-guided femoral nerve catheter insertion: a randomized, blinded trial. Anesthesiology. 2014 Aug;121(2):239-48. doi: 10.1097/ALN.0000000000000262.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.aspirus.org/for-providers
Medical staff resource
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-34431
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dexmedetomidine Verses Propofol for Paediatric MRI Brain
NCT02776189
COMPLETED
PHASE4
The Pharmacokinetics of Dexmedetomidine in Children
NCT00909935
TERMINATED
Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
NCT00607542
COMPLETED
PHASE1/PHASE2
Validation of a Production Method of Stem Cell Isolated From the Nasal Cavity for an Innovative Cell Therapy of Cleft Palate
NCT02900014
COMPLETED
NA
Dexamethasone Efficacy in HELLP I Syndrome
NCT01138839
UNKNOWN
PHASE3
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
NCT04200352
TERMINATED
PHASE3
iPad as a Distraction Tool During Facial Laceration Repair
NCT02217436
COMPLETED
NA
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
NCT03813238
COMPLETED
PHASE3
Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention
NCT04364321
UNKNOWN
NA
Pathogenesis of Adverse Drug Reactions
NCT00224952
COMPLETED
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
NCT01405950
TERMINATED
PHASE1
Outcomes of Drug Resistant Epileptic Pediatric Patient by Modified Atkins Diet
NCT07275125
NOT_YET_RECRUITING
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
NCT00205712
COMPLETED
PHASE4
Clinical Effectiveness of Late Maxillary Protraction for Cleft Lip and Palate
NCT02789787
COMPLETED
Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia
NCT00004493
COMPLETED
PHASE2
Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
NCT02982824
COMPLETED
NA
Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy
NCT01244113
COMPLETED
NA
Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet
NCT00912990
TERMINATED
NA
Intranasal Dexmedetomidine Sedation for Pediatric CT Imaging
NCT01900405
UNKNOWN
Isoflurane-induced Neuroinflammation in Children With Hydrocephalus
NCT02512809
TERMINATED
PHASE3
Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy
NCT02261753
TERMINATED
NA
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
NCT02829827
TERMINATED
PHASE2
Use of Metformin in Treatment of Childhood Obesity
NCT02274948
COMPLETED
PHASE4
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT01901588
COMPLETED
PHASE4
Docosahexaenoic Acid (DHA) Supplementation in Amblyopia
NCT03402789
WITHDRAWN
PHASE1/PHASE2